Benzodiazepines, Serum or Plasma, Quantitative

2010445
copy
 

Copy Utility


emailprint
Example Reports
Negative
Positive

Ordering Recommendation

Optimize drug therapy and monitor patient adherence.

Mnemonic

BENZO SP

Methodology

Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Performed

Tue, Fri

Reported

1-5 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).

Specimen Preparation

Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 1 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Gel separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Hemolyzed specimens.

Remarks
Stability

After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years (Avoid repeated freeze/thaw cycles)

Reference Interval

Effective November 16, 2015

Drugs Covered Cutoff Concentrations
Alprazolam 5 ng/mL
Alpha-hydroxyalprazolam 5 ng/mL
Clonazepam 5 ng/mL
Chlordiazepoxide 20 ng/mL
7-aminoclonazepam 5 ng/mL
Diazepam 5 ng/mL
Lorazepam 20 ng/mL
Alpha-hydroxymidazolam 20 ng/mL
Midazolam 20 ng/mL
Nordiazepam 20 ng/mL
Oxazepam 20 ng/mL
Temazepam 20 ng/mL

Interpretive Data

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry.

Positive cutoff: 20 ng/mL unless specified below:
Diazepam 5 ng/mL
Alprazolam 5 ng/mL
Alpha-hydroxyalprazolam 5 ng/mL
Clonazepam 5 ng/mL
7-aminoclonazepam 5 ng/mL

For medical purposes only; not valid for forensic use.

Identification of specific drug(s) taken by specimen donor is problematic due to common metabolites, some of which are prescription drugs themselves. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

80346 (Alt code: G0480)

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
2010447 Diazepam, S/P, Quant 3548-5
2010448 Nordiazepam, S/P, Quant 3537-8
2010449 Oxazepam, S/P, Quant 59730-2
2010450 Temazepam, S/P, Quant 10343-2
2010451 Lorazepam, S/P, Quant 3724-2
2010452 Alprazolam, S/P, Quant 3312-6
2010453 Alpha-hydroxyalprazolam, S/P, Quant 27921-6
2010454 Clonazepam, S/P, Quant 3494-2
2010455 7-aminoclonazepam, S/P, Quant 28059-4
2010459 Midazolam, S/P, Quant 3821-6
2012676 Chlordiazepoxide, S/P, Quant 3457-9
2012677 Alpha-hydroxymidazolam, S/P, Quant 69797-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

Benzodiazepines, Serum or Plasma, Quantitative